FDA Briefing Docs Appear Positive For Abbott's Absorb, But Adverse Events Highlighted
This article was originally published in The Gray Sheet
Executive Summary
An FDA panel meets March 15 to discuss Abbott's PMA for the firm's fully absorbable Absorb scaffold. Pre-meeting materials give a generally positive view of the device, but they highlight some elevated adverse-event rates.
You may also be interested in...
Diagnostics A Bright Spot In Lackluster US Interventional Cardiology Market
The US Market for interventional cardiology products, which includes diagnostic and therapeutic products, is anticipated to expand from an estimated $3.3 billion in 2015 to roughly $3.6 billion in total product sales by the year 2020. One bright spot in this otherwise lackluster market is the interventional diagnostic products segment, which is projected to grow at CAGR of 4.7% and reach almost $1 billion by 2020, according to a report by Medtech Insight.
Despite Panel Thumbs-Up, Analysts Downplay Absorb Market Impact
While a panel of FDA experts almost unanimously voted to recommend Abbott's fully bioabsorbable Absorb scaffold, analysts say the stent is unlikely to take significant market share, at least in its current form.
Absorbing Debate: Boston Sci, Abbott Differ On Whether The Future Of Stents Is To Disappear
Competing visions of the future of percutaneous coronary interventions were on display at TCT year, with Boston Scientific pushing its Synergy bioabsorbable polymer-coated, drug-eluting metal stent platform as the better long-term option to fully-resorbable scaffolds of the type Abbott is first out of the gate with.